(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Evan Yu discussing updated follow-up of the KEYNOTE-365 Cohort A trial. Data from the phase I/II KEYNOTE-365 study previously showed antitumor activity and acceptable safety of pembrolizumab + olaparib in patients with molecularly unselected, docetaxel-pretreated mCRPC enrolled in cohort A. At the ESMO 2021 congress, Dr. Yu and colleagues presented updated results for all patients after a minimum of 11.4 months of follow-up.